Prognostic Factors in Childhood Acute Lymphoblastic Leukemia: Correlation with Treatment Response

  • Y. Ravindranath
Part of the Developments in Oncology book series (DION, volume 33)


In 1949 Dr. Zuelzer, in his note on progress in pediatric hematology, made a then passing observation that in childhood ALL, the level of WBC at diagnosis has a bearing on survival (1). He noted, in a group of children with leukemia treated before the days of chemotherapy, that those presenting with WBC 10,000 at diagnosis, survived longer than those presenting with higher WBC counts. Some nineteen years later in 1968, Hardisty and Till (2) observed that children with ALL presenting with mediastinal mass (ALL + MM) have a poor outcome and show distinctly different clinical characteristics and thus, may have a biologically different form of ALL compared to others. In a later study (3) we confirmed this and showed that children with ALL + MM tend to have higher WBC, higher hemoglobin and platelet counts at presentation; that this presentation is seen more often in boys of older age and that they relapse early and thei survival is shorter. From these modest beginnings we have come a long way in recognizing that childhood ALL is a heterogeneous disease both in terms of clinical presentation and biologic characteristics. It is now well accepted that treatment has to be “tailored”, keeping in mind the clinical prognostic factors and immunologic subtypes of ALL.


Acute Lymphoblastic Leukemia Mediastinal Mass Central Nervous System Relapse Childhood Acute Lymphoblastic Leukemia Pediatric Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zuelzer WW: Current trends in hematology. Pediatrics 4: 269, 1949.PubMedGoogle Scholar
  2. 2.
    Hardisty RM, Till MW: Acute leukemia 1959–1964: Factors affecting prognosis. Arch. Dis. Child. 43: 107–115, 1969.CrossRefGoogle Scholar
  3. 3.
    Ravindranath Y, Kaplan J, Zuelzer WW: Significance of mediastinal mass in acute lymphoblastic leukemia. Pediatrics 55: 889–893, 1975.PubMedGoogle Scholar
  4. 4.
    Pullen DJ, Boyett JM, Crist W et al: Pediatric oncology group utilization of immunologic markers in the designation of acute lymphoblastic leukemia (ALL) subgroups. Influence on treatment response. NY Acad. Sci. 428: 26–48, 1984.CrossRefGoogle Scholar
  5. 5.
    Pullen DJ, Sullivan MP, Falletta JM et al: Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: Results and prognostic factors. Blood 60: 1159–1168, 1982.PubMedGoogle Scholar
  6. 6.
    Miller DR, Leikin S, Albo V et al: Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children’s cancer group report. Cancer Treat. Rep. 64: 381–392, 1980.PubMedGoogle Scholar
  7. 7.
    Vogler LB, Crist WM, Bockman DE et al: Pre B-cell leukemia. A new type of childhood lymphoblastic leukemia. N. Eng. J. Med. 298: 872, 1978.CrossRefGoogle Scholar
  8. 8.
    Crist W, Boyett J, Roper M et al: Pre B-cell leukemia responds poorly to treatment: A pediatric oncology group study. Blood 63: 407–414, 1984.PubMedGoogle Scholar
  9. 9.
    Baumer J, Mott M: Sex and prognosis in childhood acute lymphoblastic leukemia. Lancet II: 128–129, 1978.CrossRefGoogle Scholar
  10. 10.
    Sather H, Miller DR, Nesbit M et al for the children’s cancer study group: Differences in prognosis for boys and girls with acute lymphoblastic leukemia. Lancet I: 739–743, 1981.CrossRefGoogle Scholar
  11. 11.
    Ravindranath Y, Bhambhani K, Kelly JO et al: Central nervous system prophylaxis with intermittent intrathecal methotrexate and fractional radiation in childhood acute lymphoblastic leukemia. In: Central Nervous System Leukemia — Prevention and Treatment, Mastrangelo R, Poplack DG, Riccardi R (eds), Martinus Nijhoff, 1983.Google Scholar
  12. 12.
    George S, Aur RJA, Mauer A, Simone J: A reappraisal of the results of stopping therapy in childhood leukemia. N. Eng. J. Med. 300: 269–273, 1979.CrossRefGoogle Scholar
  13. 13.
    Greaves M, Janossy G, Peto J, Kay H: Immunologically defined subclasses of acute lymphoblastic leukemia in children: Their relationship to presentation features and prognosis. Brit. J. Haemat. 48: 179–197, 1981.PubMedGoogle Scholar
  14. 14.
    Sallan SE, Ritz J, Pesando J et al: Cell surface antigens: Prognostic implications in childhood acute lymphoblastic leukemia. Blood 55: 395–402, 1980.PubMedGoogle Scholar
  15. 15.
    Chessells JM, Hardisty RM, Rapson NT et al: Acute lymphoblastic leukemia in children: Classification and prognosis. Lancet II: 1307–1309, 1977.CrossRefGoogle Scholar
  16. 16.
    Secker-Walker LM, Lawler SD, Hardisty RM: Prognostic implications of chromosome findings in acute lymphoblastic leukemia at diagnosis. Br. Med. J. 2: 1529–1530, 1978.PubMedCrossRefGoogle Scholar
  17. 17.
    Henze G, Langermann HJ, Ritter J et al: Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: A report from the BFM study group. In: Haematology and Blood Transfusion: Modern Trends in Human Leukemia IV, Vol 26, Neth R, Gallo RC, Graf H (eds), Berlin, Springer-Verlag, 1981, p. 87.Google Scholar
  18. 18.
    Henze G, Lampert F, Langermann HJ et al: Prognosis of acute lymphoblastic leukemia related to initial findings and treatment. In: 13th International Cancer Congress, Part D, Research and Treatment, Alan R. Liss, New York, 1983, pp. 445–449.Google Scholar
  19. 19.
    Sallan SE, Hitchcock-Bryan S, Gelber R et al: Influences of intensive asparaginase in the treatment of childhood non-T acute lymphoblastic leukemia. Cancer Res. 43: 5601–5607, 1983.PubMedGoogle Scholar
  20. 20.
    Palmer MK, Hann IM, Jones PM, Evans DI: A score at diagnosis for predicting length of remission in childhood acute lymphoblastic leukemia. Brit. J. Cancer 42: 841–849, 1980.PubMedCrossRefGoogle Scholar
  21. 21.
    Ravindranath Y. Unpublished observations.Google Scholar
  22. 22.
    Aur RJA, Simone JV, Hustu HO et al: Central nervous system therapy and combination chemotherapy lymphocytic leukemia. Blood 37: 272–281, 1971.PubMedGoogle Scholar
  23. 23.
    Zuelzer WW, Ravindranath Y, Lusher JM et al: IMFRA (intermittent intrathecal methotrexate and fractional radiation) plus chemotherapy in childhood leukemia. Am. J. Hematol. 1: 191–199, 1976.CrossRefGoogle Scholar
  24. 24.
    Haghbin M, Murphy ML, Tan C et al: A long term clinical follow up of children with intensive chemotherapy regimens. Cancer (Phila)46: 241–252, 1980.CrossRefGoogle Scholar
  25. 25.
    Sullivan MP, Chen T, Dyment PG et al: Equilivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: A pediatric oncology group study. Blood 60: 948–958, 1982.PubMedGoogle Scholar
  26. 26.
    Freeman AI, Weinberg V, Brecher ML et al: Comparison of intermediate-dose methotrexate with cranial irradiation for the post induction treatment of acute lymphocytic leukemia in children. N. Eng. J. Med. 308: 477–484, 1983.CrossRefGoogle Scholar
  27. 27.
    Moe PJ, Seip M: High dose methotrexate in acute lymphocytic leukemia in childhood. Acta. Paediatr. Scand. 67: 265–268, 1978.PubMedCrossRefGoogle Scholar
  28. 28.
    Nesbit ME Jr, Sather HN, Robison LL et al: Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukemia: Comparison of 1800 rad and 2400 rad. A report for children’s cancer study group. Lancet I: 461–466, 1981.CrossRefGoogle Scholar
  29. 29.
    Coccia PF, Bleyer WA, Siegel SE et al for the Children’s Cancer Study Group: Reduced therapy for children with good prognosis acute lymphoblastic leukemia. Blood 58: 1372, 1981.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • Y. Ravindranath

There are no affiliations available

Personalised recommendations